Excellence is just the beginning.


French German Italian Portuguese Russian

Alcohol-Induced Liver Decompensation Treatment Study

Clinical Trial Title: 
A study to assess safety and efficacy of ELAD® in subjects with alcohol-induced liver decompensation (AILD).
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Nikunj Shah, MD
Clinical Trial Protocol Description: 

ELAD is an investigational human liver cell-based treatment designed to improve survival of subjects with liver failure by providing liver support continuously for up to five days. This study specifically focuses on individuals with alcohol-induced liver decompensation (AILD). Overall, 150 patients will be recruited for this study. At Rush University Medical Center, we expect to enroll 5 patients. The treatment will be assigned randomly.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Be 18-49 years old.
  • Be diagnosed with acute alcoholic hepatitis.
  • Have a bilirubin greater than or equal to 16 mg/dL.

You will be excluded from the study if any of the following criteria apply to you:

  • Are on dialysis.
  • Have liver disease related to homozygous hemachromotosis, Wilson’s Disease, have non-alcoholic fatty liver disease, or Budd-Chiari Syndrome.
  • Are unable to provide an address for follow-up home health visits.

This is a partial list of elgibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Clinical Trial Area: 
Liver, Biliary and Pancreatic Disorders
Contact Email: 
Contact Phone: 
(312) 563-3919
Contact Name: 
Diana Giczewski